We encourage individuals interested in these treatment options to schedule a consultation with our experienced team to determine the most suitable strategy based on their medical history and weight loss objectives
Send us your questions, and we will do our best to tackle them
The main findings so far are dose-dependent weight loss in phase 2 studies, frequent gastrointestinal side effects, and ongoing questions about long-term safety, eligibility, and approval
Get this wrong and everything downstream falls apart
With 23% of US households already including at least one GLP-1 user, spending on savory snacks, baked goods, and calorie-dense convenience food falling measurably, and JPMorgan projecting $30 to $55 billion in food and beverage revenue reduction by 2030 to 2034, the portfolio implications are real and unevenly distributed